Physician profile
Daniel Kuehler
NPI 1871020313
$7,071.08
in general payments reported to CMS, 2019-2025
13 companies · $4,208 in 2025
The $4,208 reported for 2025 was more than what 83% of Transplant Surgery providers received nationally (typical 2025 total: $423).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $97.72 · 2021: $167 · 2024: $2,598 · 2025: $4,208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,848 · Education: $2,500 · Food and Beverage: $458.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,847.80 |
| Education | $2,500.00 |
| Food and Beverage | $458.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,107.85 | 2025 | |
| Transmedics, INC. | $2,339.95 | 2024 | Organ Care System |
| Boston Scientific Corporation | $128.00 | 2024 | Therasphere Y90 Glass Microspheres 10 Gbq |
| Medtronic, INC. | $103.78 | 2021-2024 | Signia |
| Olympus America INC. | $97.72 | 2019 | |
| W. L. Gore & Associates, INC. | $96.00 | 2021 | |
| Merck Sharp & Dohme LLC | $46.73 | 2024-2025 | Prevymis |
| Octapharma USA, INC. | $31.39 | 2025 | Fibryga |
| Gilead Sciences, INC. | $30.10 | 2024 | |
| Pacira Pharmaceuticals Incorporated | $27.94 | 2024 | Exparel |
| Ipsen Biopharmaceuticals, INC | $26.63 | 2025 | Bylvay |
| Intercept Pharmaceuticals, INC. | $17.58 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.41 | 2025 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Kuehler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.